XASEMLSS
Market cap67mUSD
Dec 23, Last price
0.87USD
1D
-5.95%
1Q
-11.22%
Jan 2017
-37.86%
Name
Milestone Scientific Inc
Chart & Performance
Profile
Milestone Scientific Inc. designs, develops, and commercializes diagnostic and therapeutic injection technologies, and devices for medical, dental, and cosmetic use in the United States, China, and internationally. The company operates in two segments, Dental and Medical. Its products include CompuDent and STA Single Tooth Anesthesia System that are used for all dental procedures that require local anesthetic. The company also offers CompuFlo, a computer-controlled drug delivery system for the painless delivery of drugs, anesthetics, and other medicaments, as well as for the aspiration of bodily fluids or previously injected substances; and disposable injection handpiece for the tactile control during the injection. In addition, it provides CompuFlo Epidural, a computer controlled anesthesia system for use in various medical applications. Further, the company offers CompuMed for use in various medical procedures performed in plastic, hair restoration, and colorectal surgery, as well as podiatry, dermatology, orthopedics, and various other disciplines. Milestone Scientific Inc. was incorporated in 1989 and is headquartered in Livingston, New Jersey.
IPO date
Nov 03, 1995
Employees
20
Domiciled in
US
Incorporated in
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 9,827 11.60% | 8,806 -14.54% | 10,305 89.52% | |||||||
Cost of revenue | 3,736 | 5,055 | 4,871 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 6,091 | 3,751 | 5,434 | |||||||
NOPBT Margin | 61.98% | 42.59% | 52.73% | |||||||
Operating Taxes | (67) | 333 | ||||||||
Tax Rate | 0.01% | |||||||||
NOPAT | 6,091 | 3,817 | 5,433 | |||||||
Net income | (6,929) -20.41% | (8,706) 22.29% | (7,119) -4.91% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 2,570 | 4,598 | ||||||||
BB yield | -5.12% | -3.24% | ||||||||
Debt | ||||||||||
Debt current | 227 | 101 | 90 | |||||||
Long-term debt | 678 | 893 | 1,084 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | (5,049) | (7,721) | (13,591) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (5,326) | (6,032) | (4,018) | |||||||
CAPEX | (5) | (9) | (15) | |||||||
Cash from investing activities | (2,972) | (9) | (15) | |||||||
Cash from financing activities | 2,561 | (9) | 4,573 | |||||||
FCF | 4,206 | 3,912 | 6,917 | |||||||
Balance | ||||||||||
Cash | 5,954 | 8,715 | 14,764 | |||||||
Long term investments | ||||||||||
Excess cash | 5,463 | 8,275 | 14,249 | |||||||
Stockholders' equity | (123,050) | (116,560) | (107,789) | |||||||
Invested Capital | 131,572 | 127,064 | 124,591 | |||||||
ROIC | 4.71% | 3.03% | 4.48% | |||||||
ROCE | 71.48% | 35.71% | 32.34% | |||||||
EV | ||||||||||
Common stock shares outstanding | 72,776 | 70,607 | 68,830 | |||||||
Price | 0.69 43.73% | 0.48 -76.70% | 2.06 -2.83% | |||||||
Market cap | 50,208 48.14% | 33,892 -76.10% | 141,790 6.06% | |||||||
EV | 45,373 | 25,951 | 128,046 | |||||||
EBITDA | 6,242 | 3,895 | 5,508 | |||||||
EV/EBITDA | 7.27 | 6.66 | 23.25 | |||||||
Interest | 55 | 16 | ||||||||
Interest/NOPBT | 1.46% | 0.30% |